Adaptive biotechnologies stock.
Adaptive Biotechnologies ( ADPT) reported Q3 2023 earnings per share (EPS) of -$0.35, missing estimates of -$0.34 by 2.64%. In the same quarter last year, Adaptive Biotechnologies 's earnings per share (EPS) was -$0.32. Adaptive Biotechnologies is expected to release next earnings on 02/19/2024, with an earnings per share (EPS) …
Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued.Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ...As of March 31, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.83. Adaptive Biotechnologies Corp is up 4.87% from its previous closing price of $8.42. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.21 and $8.67. Currently, there are 143.06 million shares of Adaptive ...SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a translational collaboration with Takeda to …Adaptive Biotechnologies (NASDAQ:ADPT) has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $10.88 versus the current price of ...
Feb 14, 2023 · Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ (0.28) $ (0.43) $ (1.40) $ (1.48) Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 143,054,722 141,228,918 142,515,917 140,354,915 Feb 14, 2023 · Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted $ (0.28) $ (0.43) $ (1.40) $ (1.48) Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted 143,054,722 141,228,918 142,515,917 140,354,915 Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.May 3, 2023 · Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago. These ...
Oct 17, 2023 · The latest Adaptive Biotechnologies Corporation Registered Shs stock prices, stock quotes, news, and ADPT history to help you invest and trade smarter. Oct 19, 2023 · Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%. You can buy or sell ADPT and other ETFs, options, and stocks. Sign up. About ADPT. Adaptive Biotechnologies Corp. engages in the development of an immune ...Nov 9, 2023 · SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...
May 26, 2023 · The growth-stock investor added to her stakes in UiPath (PATH 26.72%), Prime Medicine (PRME 11.02%), and Adaptive Biotechnologies (ADPT 7.31%) on Thursday. What does Wood see in these three ...
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 24.32% and 1.17%, ... Do the numbers hold clues to what lies ahead for the stock? Skip to main content.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic …May 12, 2023 · Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. Adaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive …Adaptive Biotechnologies (ADPT Quick Quote ADPT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a ...Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight …Apr 12, 2023. Listen to this article 3 min. Mark Adams, chief operating officer of Adaptive Biotechnologies Corp. (Nasdaq: ADPT), is moving on from the Seattle-based biotech company. In a Tuesday ...
Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued.Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.51% and 0.31%, ... Do the numbers hold clues to what lies ahead for the stock? Adaptive Biotechnologies ...Analyst Recommendations on Adaptive Biotechnologies Corporation. Morgan Stanley Cuts Adaptive Biotechnologies' Price Target to $10 From $13, Keeps Equalweight Rating. Oct. 24. MT. BofA Securities Trims Price Target on Adaptive Biotechnologies to $9 From $11, Maintains Buy Rating. Oct. 20. May 12, 2023 · Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen closed nearly 83% …Adaptive Biotechnologies Corporation (ADPT) Stock Price, Quote, News & Analysis Save 45%! Get early access to our annual Black Friday Sale » ADPT Adaptive …
Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.
Adaptive Biotechnologies stock rallies 14% on upgrade to Overweight at Piper Sandler SA News Wed, Dec. 21, 2022 Adaptive Biotechnologies GAAP EPS of -$0.32 beats by $0.06, revenue of $47.8M misses ...Apr 25, 2023 · Adaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s P ... Of course Adaptive Biotechnologies may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders ...Adaptive’s net loss came in at $50.3 million, compared to $45.3 million in the same period last year. The company’s stock dipped nearly 5% today. Adaptive Biotechnologies hired Goldman Sachs ...Oct 17, 2023 · The latest Adaptive Biotechnologies Corporation Registered Shs stock prices, stock quotes, news, and ADPT history to help you invest and trade smarter. View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.
THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing …
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings …
BeiGene Ltd. Stock Performance and Financial Outlook: November 2023 Analysis. On November 7, 2023, BeiGene Ltd. (BGNE) experienced some fluctuations in its stock performance. The previous day’s close was recorded at $196.15, and the stock opened at $194.08. Throughout the day, the stock traded within a range of $194.08 to $197.57.Nov 2, 2023 · Stock. Stock Quote & Chart ... Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune ... Adaptive Biotechnologies Corporation published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 10 January 2022 20:27:03 UTC .0.86%. $864.11M. ADPT | Complete Adaptive Biotechnologies Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Maneesh Tandon. Employment: Roche (I) Stock and Other Ownership Interests: Roche Pharma AG. Anna-Maria Fink. Research Funding: Celgene/Bristol Myers Squibb (Inst), AstraZeneca (Inst)Wall Street Stock Market & Finance report, prediction for the future: You'll find the Adaptive Biotechnologies share forecasts, stock quote and buy / sell signals below. According to present data Adaptive Biotechnologies's ADPT shares and potentially its market environment have been in bearish cycle last 12 months (if exists).Nov 30, 2023 · The stock price for . Adaptive Biotechnologies (NASDAQ: ADPT) is $4.4 last updated Today at November 30, 2023 at 9:44 PM UTC. Q Does Adaptive Biotechnologies (ADPT) pay a dividend? Adaptive Biotechnologies Corporation (ADPT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Adaptive Biotechnologies ...
SEATTLE, July 15, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $40.00 ...Nov 7, 2023 · SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ... Traditional biotechnology is the use of natural organisms by humans to create or modify foods or other useful products. Examples of traditional biotechnology include using yeasts for fermentation and practicing selective seed collection to ...52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. RSS Feeds.Instagram:https://instagram. fha loans in ohiofutures trading coursespaper trading simulator freec.m.i Adaptive Biotechnologies (NASDAQ:ADPT shareholders incur further losses as stock declines 17% this week, taking three-year losses to 76% can you buy stocks on etradeblue chip stocks with good dividends A high-level overview of Adaptive Biotechnologies Corporation (ADPT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. upside stocks Of course Adaptive Biotechnologies may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders ...Adaptive Biotech hires Goldman Sachs to explore ‘strategic alternatives’ for key business lines With revenues declining and net losses increasing, Seattle-based Adaptive Biotechnologies on Thursday said it hired Goldman Sachs to help conduct a review of strategic alternatives for its Minimal Residual Disease (MRD) and Immune Medicine …Nov 7, 2023 · SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ...